skip to content

Retirement Weekly

News and analysis for those planning for or living in retirement

From MarketWatch Retirement: 

Eli Lilly’s positive results from a seen as ‘potentially very important.’ Eli Lilly’s positive Phase 3 trial showed that the drug donanemab “significantly slowed cognitive and functional decline” in patients with early symptomatic Alzheimer’s disease.

What happens to if no debt-ceiling deal is reached? Failure...